Patents by Inventor Yinong Xie

Yinong Xie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SHP2 INHIBITORS AND USES THEREOF
    Publication number: 20230010886
    Abstract: Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 12, 2023
    Inventors: Yinong XIE, Lee E. BABISS
  • Azetidine derivative, preparation method therefor, and use thereof
    Patent number: 11045455
    Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: June 29, 2021
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Yinong Xie, Zejin You, Zhiwen Deng, Jun Zhu, Ao Wang, Yan Feng, Dong Long, Hong Zeng, Hongmei Song, Qijun Ye, Wei Qi, Donghai Su, Lichun Wang, Jingyi Wang
  • APPARATUS FOR REMOVING BAD ODOR FROM TOILET
    Publication number: 20200385370
    Abstract: Compounds of Formula I as IRAK4 inhibitors are disclosed. The pharmaceutical compositions comprising compounds of formula I, methods of synthesis of these compounds, methods of treatment for diseases associated with IRAK-4 such as inflammatory diseases and autoimmune diseases using these compounds or compositions containing these compounds are also disclosed.
    Type: Application
    Filed: October 29, 2018
    Publication date: December 10, 2020
    Inventors: Yinong XIE, Lee E BABISS
  • AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF
    Publication number: 20200147062
    Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
    Type: Application
    Filed: January 16, 2020
    Publication date: May 14, 2020
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Yinong XIE, Zejin YOU, Zhiwen DENG, Jun ZHU, Ao WANG, Yan FENG, Dong LONG, Hong ZENG, Hongmei SONG, Qijun YE, Wei QI, Donghai SU, Lichun WANG, Jingyi WANG
  • SHP2 inhibitors and uses thereof
    Patent number: 10561655
    Abstract: Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: February 18, 2020
    Assignee: SYNBLia Therapeutics, Inc.
    Inventors: Yinong Xie, Lee E. Babiss
  • SHP2 INHIBITORS AND USES THEREOF
    Publication number: 20190290649
    Abstract: Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 26, 2019
    Inventors: Yinong Xie, Lee E. Babiss
  • AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF
    Publication number: 20190060291
    Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
    Type: Application
    Filed: October 24, 2018
    Publication date: February 28, 2019
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: YINONG XIE, Zejin YOU, Zhiwen DENG, Jun ZHU, Ao WANG, Yan FENG, Dong LONG, Hong ZENG, Hongmei SONG, Qijun YE, Wei QI, Donghai SU, Lichun WANG, Jingyi WANG
  • Azetidine derivative, preparation method therefor, and use thereof
    Patent number: 10159662
    Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: December 25, 2018
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Yinong Xie, Zejin You, Zhiwen Deng, Jun Zhu, Ao Wang, Yan Feng, Dong Long, Hong Zeng, Hongmei Song, Qijun Ye, Wei Qi, Donghai Su, Lichun Wang, Jingyi Wang
  • AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF
    Publication number: 20180289680
    Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
    Type: Application
    Filed: December 8, 2016
    Publication date: October 11, 2018
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Yinong XIE, Zejin YOU, Zhiwen DENG, Jun ZHU, Ao WANG, Yan FENG, Dong LONG, Hong ZHENG, Hongmei SONG, Qijun YE, Wei Qi, Donghai SU, Lichun WANG, Jingyi WANG
  • Fluorophenyl pyrazol compounds
    Patent number: 9499490
    Abstract: The present invention provides a compound of the Formula: wherein X is selected from the group consisting of, R is selected from the group consisting of H and CH3; R1 is selected from the group consisting of H, CH3, F, Cl, OCH3, C(O)OH, C(O)NH2 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: November 22, 2016
    Assignee: Eli Lilly and Company
    Inventors: Kevin Kun-Chin Liu, Yinong Xie, Liang Wu, Guoqiang Zhou
  • FLUOROPHENYL PYRAZOL COMPOUNDS
    Publication number: 20160289195
    Abstract: The present invention provides a compound of the Formula: wherein X is selected from the group consisting of, R is selected from the group consisting of H and CH3; R1 is selected from the group consisting of H, CH3, F, Cl, OCH3, C(O)OH, C(O)NH2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 6, 2016
    Inventors: Kevin Kun-Chin Liu, Yinong Xie, Liang Wu, Guoqiang Zhou
  • Imidazole based LXR modulators
    Patent number: 9000022
    Abstract: Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId and pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in treating, preventing, inhibiting or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by nuclear receptor activity, or in which nuclear receptor activity is implicated.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: April 7, 2015
    Assignee: Exelixis Patent Company LLC
    Inventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin J. Schweiger, William C. Stevens, Jr., Tie-Lin Wang, Yinong Xie
  • Modulators of LXR
    Patent number: 8703805
    Abstract: Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: April 22, 2014
    Assignee: Exelixis Patent Company LLC
    Inventors: Brett B. Busch, Brenton T. Flatt, Xiao Hui Gu, Shao Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, Jr., Tie Lin Wang, Yinong Xie
  • IMIDAZOLE BASED LXR MODULATORS
    Publication number: 20140038964
    Abstract: Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId and pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in treating, preventing, inhibiting or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by nuclear receptor activity, or in which nuclear receptor activity is implicated.
    Type: Application
    Filed: July 25, 2013
    Publication date: February 6, 2014
    Applicant: Exelixis Patent Company LLC
    Inventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin J. Schweiger, William C. Stevens, JR., Tie-Lin Wang, Yinong Xie
  • Imidazole based LXR modulators
    Patent number: 8569352
    Abstract: Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3 and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: October 29, 2013
    Assignee: Exelixis Patent Company LLC
    Inventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao-Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, Jr., Tie-Lin Wang, Yinong Xie
  • Modulators of LXR
    Patent number: 8013001
    Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: September 6, 2011
    Assignee: Exelixis, Inc.
    Inventors: Christopher D. Bayne, Alan T. Johnson, Shao Po Lu, Raju Mohan, Michael C. Nyman, Edwin J. Schweiger, William C. Stevens, Jr., Haixia Wang, Yinong Xie
  • LXR and FXR modulators
    Patent number: 7998995
    Abstract: Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: August 16, 2011
    Assignee: Exelixis Patent Company LLC
    Inventors: Brant Clayton Boren, Brett B. Busch, Xiao-Hui Gu, Vasu Jammalamadaka, Shao Po Lu, Richard Martin, Raju Mohan, Edwin Schweiger, William C. Stevens, Tie-Lin Wang, Yinong Xie, Wei Xu
  • MODULATORS OF LXR
    Publication number: 20100331295
    Abstract: Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: June 26, 2006
    Publication date: December 30, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Brett B Busch, Brenton T. Flatt, Xiao Hui Gu, Shao Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, JR., Tie Lin Wang, Yinong Xie
  • IMIDAZOLE BASED LXR MODULATORS
    Publication number: 20100075964
    Abstract: Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3 and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: June 26, 2006
    Publication date: March 25, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao-Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, Jr., Tie-Lin Wang, Yinong Xie
  • LXR and FXR Modulators
    Publication number: 20100069367
    Abstract: Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: December 7, 2007
    Publication date: March 18, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Brant Clayton Boren, Brett B. Busch, Xiao-Hui Gu, Vasu Jammalamadaka, Shao Po Lu, Richard Martin, Raju Mohan, Edwin Schweiger, William C. Stevens, Tie-Lin Wang, Yinong Xie, Wei Xu